Abstract |
To evaluate the efficacy and safety of supratarsal injection of triamcinolone acetonide in the treatment of refractory allergic keratoconjunctivitis in childhood. Thirty-five patients (70 eyes) with severe allergic keratoconjunctivitis were included in this study. Fifteen patients (42.8%) had atopic keratoconjunctivitis (AKC) and 20 (57.2%) had vernal keratoconjuncivitis (VKC). All patients underwent a bilateral supratarsal injection of 20 mg triamcinolone acetonide. Mean follow-up was 28 months (range 14-38). All patients showed a significant symptomatic improvement and partial resolution of clinical features of keratoconjunctivitis within the first 2 weeks. Corneal complications related to keratoconjunctivitis disappeared in all patients. One patient with VKC experienced ocular hypertension. No patient with AKC showed side-effects. Severe relapse of the disease was noted in 10% of eyes with VKC and in 6.7% of eyes with AKC after a mean follow-up of 9 and 11 months, respectively. Supratarsal injection of triamcinolone acetonide is effective and safe in patients with severe chronic allergic keratoconjunctivits to relieve severe inflammation associated with this disease.
|
Authors | Sonia Zaouali, Rim Kahloun, Sonia Attia, Bechir Jelliti, Manel Trigui, Salim Ben Yahia, Riadh Messaoud, Moncef Khairallah |
Journal | International ophthalmology
(Int Ophthalmol)
Vol. 32
Issue 2
Pg. 99-106
(Apr 2012)
ISSN: 1573-2630 [Electronic] Netherlands |
PMID | 22331436
(Publication Type: Journal Article)
|
Chemical References |
- Glucocorticoids
- Triamcinolone Acetonide
|
Topics |
- Adolescent
- Child
- Conjunctivitis, Allergic
(drug therapy)
- Eyelids
(drug effects)
- Female
- Glucocorticoids
(administration & dosage, adverse effects)
- Humans
- Injections, Intraocular
- Male
- Retrospective Studies
- Treatment Outcome
- Triamcinolone Acetonide
(administration & dosage, adverse effects)
- Visual Acuity
(physiology)
|